PI3K-AKT-mTOR and RASRAF-MEK-ERK pathway inhibitors showed synergistic tumor inhibition in many preclinical vitro and vivo models in NSCLC with CDK4/6 inhibitors (50–52). Here, MAP2K7 is linked to non-small cell lung carcinoma.